Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$3.85 USD
+0.04 (1.05%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Brokerage Reports
Puma Biotechnology, Inc. [PBYI]
Reports for Purchase
Showing records 41 - 60 ( 227 total )
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Nerlynx Sales Above Guidance; FDA Discussion for Alisertib Pathway Anticipated Later This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Just Kickin'' It, Sneaker Tracker April''23; Will "Air" Be The Next "Last Dance"?
Provider: Wedbush Securities Inc.
Analyst: NIKIC T
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Nerlynx Net Product Sales Beat Our Estimate; Alisertib Data Expected in 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Nerlynx Additions to Updated NCCN Guidelines For the Treatment of Breast Cancer Patients With a HER2 Mutation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Nerlynx Sales Rise; Updated SUMMIT Trial Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Interim Results From Phase 2 SUMMIT Basket Trial of Nerlynx in EGFR Exon 18-Mutant NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WRIGHT J
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Just What the Doctor Ordered; Alisertib In-Licensed
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department